Search Weight Loss Topics:

Page 19«..10..18192021..3040..»

Home » Hgh » Page 19

The Hawkesbury and District General Hospital (HGH) and its Foundation have been asking for the communitys help in donating hand-sewn masks for use at the hospital.

Patients are currently required to wear a mask before entering HGH and those arriving without one are being provided with a cloth mask, which has been sewn and donated by generous donors.

The response from the community has been wonderful. In particular, a mother-daughter team, Annette and Tiffany Jones, have stepped up to the challenge, having already made and donated more than 200 masks! This incredible donation represents many hours of work by the two, who plan to continue making and donating masks to the HGH Foundation to support the hospital over the coming months.

The donation was presented to Pierre-Luc Byham (Executive Director, HGH Foundation), Dr. Julie Maranda (Chief of Staff and Interim VP Clinical Programs, HGH), and Daniel LeBreux (Clinical Director, HGH) by Annette and Tiffany Jones.

Can you sew? HGH still needs your help. For more information, visit the HGH Foundations website at http://www.hghfoundation.org or call (613) 632-1111 ext. 21101.

Continued here:
Mother and daughter team donate more than 200 handmade masks to the HGH Foundation - The Review Newspaper

In previous columns, I was very bearish on Co-Diagnostics (NASDAQ:CODX) and XpressSpa (NASDAQ:XSPA). Both stocks are plays on testing for the novel coronavirus. However,Opko Health (NASDAQ:OPK) stock is very different from those two names.

Source: Maksim Shmeljov / Shutterstock.com

Co-Diagnostics had little revenue before developing its test for the coronavirus in less than two hours. And its coronavirus test has generated some controversy. XpresSpa has no previous experience with lab testing, has not announced any paying customers for its tests, and seems to be trying to compete with entities that are providing the test for free. The valuations of both stocks are very high.

In contrast Opkos BioReference Laboratories subsidiary has a tremendous amount of experience in obtaining and testing blood samples. Further, BioReference has announced that it has made deals to provide its coronavirus tests to large government entities. These contracts are generating a significant amount of revenue.

Finally, Opko has generated meaningful sales in past years, and it has developed a drug that looks poised to bring in significant revenue, while the valuation of OPK stock is reasonable.

Acquired by Opko in 2015 for $1.47 billion, BioReference generated $832 million of revenue in its fiscal 2014, making it Americas third-largest publicly traded lab company at that time, according to TheDarkIntelligenceGroup.

BioReference has been testing lab specimens since 1986 and has acquired many other experienced diagnostic entities over the years. Since at least 2000, its carried out genetic screening.

On the coronavirus front, BioReference signed a $150 million contract with at least four coronavirus hotspots: New York State, New Jersey, Detroit, and Florida. Its also processing tests for many hospitals.

As of July 1, it had processed almost 250,000 Covid-19 tests from nursing homes and live-in facility employees. Given all of this information, its obvious that BioReference got a lot of money to process coronavirus tests.

Opko, in partnership with Pfizer (NYSE:PFE), developed a human growth hormone drug, somatrogon. Based on data generated by a Phase 3 trial of somatrogon, the drug appears to be significantly more effective than a drug called somatropin, which is used to treat growth hormone deficiency or GHD.

According to Opko, 1 in 3,800 children in the U.S. requires human growth hormones. In 2017, there were 74 million children in the U.S. That means about 19,500 children in the U.S. have GHD and require HGH treatments. HGH treatments cost $1,000 to $5,000 per month.

Since a number of other companies HGH treatments are undergoing Phase 3 trials, but Opko has a big-time partner in Pfizer, lets assume that Opko gets 30% of the market at a price of $3,000 per month or $36,000 per year. That works out to annual revenue of $210.5 million. If Pfizer gets 30% of the revenue, Opko would still get $147 million. In 2019, Opkos revenue was $902 million.

Some parents are starting to give HGH to children who dont clinically require the hormone, and 1 in 10,000 adults have GHD. Moreover, some adults who dont have GHD are using HGH to try to combat the aging process. Some doctors could legally prescribe Opkos HGH treatment to adults. And finally, Opkos treatment could be approved in the EU. All told, I think the drug could easily generate $300 million of annual revenue for the company.

On June 1, the FDA agreed to allow Opko to conduct a Phase 2 trial of its Rayaldee drug as a treatment for patients with mild-to-moderate COVID-19. Rayaldee is a prohormone of calcitriol, which is the active form of vitamin D.

In a statement, Charles W. Bishop, the CEO of Opkos renal division said, Raising serum 25D (a derivative of Vitamin D) enables macrophages, a type of white blood cell of the immune system, to secrete potent antiviral proteins that can destroy SARS-CoV-2, the virus that causes COVID-19. It also can suppress the cytokine storm triggered by viral infection.

Theres some controversy over the link between Vitamin D and the coronavirus. Yale doctors say theres slim evidence of a link, while the University of Chicago contends that Vitamin D deficiency may raise risk of getting COVID-19.

On the other hand, there seems to be a widespread belief among medical professionals that the cytokine storm triggered by Covid-19 is a major problem, and Opko appears to be somewhat optimistic about the ability of its drug to combat that issue.

Regardless, with a vaccine potentially arriving in the fall or early next year and the FDA only authorizing a Phase 2 trial last month, the company may not have enough time to generate a large amount of sales from the indication. If it does turn out that Rayldee meaningfully helps coronavirus patients, however, the company could get a meaningful revenue bump from off-label prescribing and stockpiling by hospitals and governments.

Opko, which reported sales of $990 million in 2018, looks poised to generate strong revenue growth this year, driven by its coronavirus tests and its HGH treatment. Meanwhile, its shares are trading at a reasonable 2.4 times its trailing sales. Given these points, OPK stock is worth buying for longer-term investors.

As of this writing, Larry Ramer did not own any of the aforementioned securities. Larry has conducted research and written articles on U.S. stocks for 13 years. He has been employed by The Fly and Israels largest business newspaper, Globes. Larry began writing columns for InvestorPlace in 2015. Among his highly successful, contrarian picks have been airline stocks, oil stocks and Snap. You can reach him on StockTwits at @larryramer.

Continue reading here:
Opko Stock Is a Covid-19 Testing Name Worth Betting On - Investorplace.com

Metabolic Demands of The Human Brain

The brain is dependent on a constant supply of glucose as it doesnt have any storage capacity in itself to store glucose as glucagon. In addition to this, the brain doesnt use alternative sources of fuel such as fatty acids which is believed to be due to an evolutionary protective mechanism from the harmful effects of fatty acid oxidation. Thus, due to its reliance on glucose for fuel the brain can only derive its energy via aerobic glycolysis and oxidative phosphorylation. Although it can also use ketone bodies, this fuel source is limited and not as efficient as glucose.

Read Also: HGH Improves Memory In Stroke Victims Study Shows

The brain is a highly heterogeneous organ in terms of its functions and cell type. Different nerve cells have a variety of functions and thus a variable demand for energy. More than 20% of the bodys energy is consumed by the brain although it accounts for less than 2% of the total body mass. This energy as stated above is produced by aerobic glycolysis which is dependent on oxygen therefore oxygen levels is a significant factor that influences brain cells functionality. Despite a large number of studies conducted on understanding the metabolic processes of the brain, the amount of oxygen consumption by the brain has not been known until now.

Neurobiologists from LMU have recently calculated the amount of oxygen the human brain consumes based on the activity of some nerve cells. For the first time in the history of medical science, neurobiologists Hans Straka, Suzan zugur, and Lars Kunz have discovered a method to directly measure the oxygen consumed by the brain by correlating it with the neural cell functions.

Read Also: Brain Cancer: A Promising New Treatment for Destroying Aggressive Glioblastoma Cell

Using electrochemical sensors in tadpoles, the neuroscientists determined the concentration of oxygen in the brain. This technique enabled them to control the oxygen levels within the brain while simultaneously inhibiting brain function by controlling nerve cell functional activity using pharmacological inhibitors of neurotransmitters. By examining eye movements while controlling nerve cell activity, the neurobiologists analyzed the association of nerve cell function with oxygen consumption.

We have found that the brain is anoxic in a normal air-saturated environment, which means that no oxygen can be measured, said Straka. Read Also: New Brain Surgery Technique Makes Cancer Cells More Visible for RemovalAny oxygen consumed by the nerve cells is immediately utilized for aerobic glycolysis for energy. However, if oxygen saturation levels of the atmosphere were twice the normal concentration, the utilization of oxygen for energy was saturated creating an abundance of oxygen within the brain. For nerve cell activity, only half of the oxygen was used while the remaining half was required by glial cells to maintain the basic metabolic rate of both glial cells and nerve cells. But in situations of increased brain activity, more oxygen was utilized for nerve cell activity than basic metabolic rate.

Understanding the influence of oxygen saturation or deficiency with brain activity is a crucial step to further research the mechanism by which our brain processes information.

Relationship between oxygen consumption and neuronal activity in a defined neural circuit

Read more here:
Neurobiologists Calculate Oxygen Consumed By The Brain - Gilmore Health News

Intermittent fasting is one of the top lifestyle trends this year.

And thats not only because we came out of COVID-19 looking a little chubbier and tubbier, but also because it has proven results with (relatively) little effort required.

Nevertheless, as with all diets (and diet fads), its important to be properly informed before embarking on a journey of changing your eating habits.

Here, Dr Priya Khorana, founder and CEO of Lifestyle Nutrition Consulting Co in Bangkok, gives us the ultimate low-down on intermittent fasting, from the perspective of someone who really knows a thing or two about this stuff. Read on, take note, and decide for yourself if youre ready to (stomach) rumble.

Intermittent fasting (IF) is not a diet. It is a timed approach to eating, and unlike a restricted fad diet, it does not specify what foods a person should eat or avoid. To put simply; IF does not change what you eat, it changes when you eat.

It may have some health benefits, including weight loss and improved insulin sensitivity, but it is not suitable for everyone and should be done with careful consideration. People with advanced diabetes or who are on medications for diabetes, people with a history of eating disorders like anorexia and bulimia, and pregnant or breastfeeding women should not attempt intermittent fasting unless under the close supervision of a physician who can monitor them.

Having said that, there are some evidence-based benefits of IF. In men, it has shown to reduce insulin resistance and lower blood sugar levels (and thereby reducing the risk of type 2 diabetes). It has also been shown to reduce oxidative damage and inflammation, thereby slowing down effects of ageing. Lastly, the insulin levels drop human growth hormone (HGH) increases, which helps facilitate fat burning and muscle gain.

Depending on your IF approach, youre either shortening the eating window each day, or engaging in 24-hour fasts one or more times a week. One of the most popular approaches is the 16:8 method, which is when you fast for an eight-hour window this is often the approach I go for. It is vital to stress that folks use an eating approach that works and is sustainable to them.

The 16:8 MethodThis is also called the Leangains Protocol, and involves skipping breakfast and restricting your daily eating period to 8 hours, such as 1-9pm. Then you fast for 16 hours in between.

The Eat-Stop-EatThis involves fasting for 24 hours, once or twice a week. For example, you may not eat from dinner one day until dinner the next day.

The 5:2 DietWith this method, you consume only 500-600 calories on two non-consecutive days of the week, but eat normally the other 5 days.

As a doctor of nutrition, I will always recommend foods for improved health, including high-fiber, unprocessed, whole foods in all colours and varieties. A mostly plant-based Mediterranean-style diet has been linked to improved health benefits, and in this case, I will suggest this way of life even whilst fasting. Making sure you are nourishing your body as effectively prior to starting your fast will help prevent any feelings of being hangry during the fast.

It is also vital for me to suggest that if you are embarking on an IF journey, staying hydrated is key. Fasting can come with some initial side effects, such as increased hunger, low blood sugar, headache, irritability, dizziness, and fatigue so please embark with caution.

Limiting your dining window does not give you an excuse to binge eat especially on unhealthy foods because you will not see the benefits. Eating unwholesome (read: junk) food in a shortened feeding window on the IF diet may also put you at risk of deficiencies in key nutrients such as calcium, iron, protein, and fiber, all of which are essential for normal biological function.

What you need to do is consume a diet rich in fruits and vegetables, whole-grains, and sufficient lean protein and healthy fat boosting important antioxidants and nutrients which all result in an increased lifespan and reduces the risks of developing lifestyle related chronic diseases.

What is important to emphasise is that the goal of IF is to maintain a healthy amount of calories for your body during the fast so you do not rebound eat.

For those starting out, I suggest implementing a 12-hour fasting/12-hour eating window and building up from there, eventually finding a schedule that works best for you. The most important thing is breaking your fast with fresh, unprocessed, nutrient-dense whole foods, prioritising healthy sources of protein and good fats, all while limiting junk foods that negate any benefits of IF.

This story first appeared on Lifestyle Asia Bangkok

(Featured and main photos: Brooke Lark/ Unsplash)

See the article here:
Here's everything you need to know about intermittent fasting - Prestige Online

New Jersey, United States,- Market Research Intellect sheds light on the market scope, potential, and performance perspective of the Global Human Growth Hormone (hGH) Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the global Human Growth Hormone (hGH) market.

The research study includes the latest updates about the COVID-19 impact on the Human Growth Hormone (hGH) sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Human Growth Hormone (hGH) manufacturers/companies operating at both regional and global levels:

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=234827&utm_source=3WN&utm_medium=888

The Human Growth Hormone (hGH) market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Human Growth Hormone (hGH) market.

This study analyzes the growth of Human Growth Hormone (hGH) based on the present, past and futuristic data and will render complete information about the Human Growth Hormone (hGH) industry to the market-leading industry players that will guide the direction of the Human Growth Hormone (hGH) market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Human Growth Hormone (hGH) market. Additionally, it includes a share of each segment of the Human Growth Hormone (hGH) market, giving methodical information about types and applications of the market.

Reasons for Buying Human Growth Hormone (hGH) Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Human Growth Hormone (hGH) market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=234827&utm_source=3WN&utm_medium=888

In the end, the Human Growth Hormone (hGH) market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Human Growth Hormone (hGH) market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Building Information Modeling (BIM) Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Parcel Sortation Systems Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Intelligent Pigging Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Sensor Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Smart Card Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Follow this link:
Human Growth Hormone (hGH) Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News

Supports the investigation of TransCon hGH for treatment of growth hormone deficiency in the pediatric population from 6 months to less than 18 years of age

Company on track to submit European marketing application in third quarter 2020

No additional studies required

COPENHAGEN, Denmark, July 06, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S(Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced that it received a positive opinion from the Paediatric Committee (PDCO) of the European Medicines Agency (EMA) on its agreement with the proposed Paediatric Investigation Plan (PIP) for TransCon hGH (lonapegsomatropin), an investigational long-acting once-weekly prodrug of somatropin (human growth hormone or hGH) in development for treatment of growth hormone deficiency (GHD). The positive opinion is based on the non-clinical safety program, as well as data from the three phase 3 clinical trials provided to PDCO from the ongoing TransCon hGH development program, which will be included in the upcoming Marketing Authorisation Application (MAA).

The PIP opinion from PDCO endorsed the TransCon hGH program as acceptable for assessment of safety and efficacy for the use of TransCon hGH as a treatment for growth hormone deficiency in children from 6 months to less than 18 years of age, mirroring the population covered by the studies conducted in the program.

We are delighted to receive the positive opinion from PDCO regarding our PIP, which is based on a comprehensive data package from our non-clinical and clinical development program for TransCon hGH. As planned, we will move forward with our marketing application submission in Europe this quarter, said Dana Pizzuti, M.D., Ascendis Pharmas Senior Vice President of Development Operations. We believe this opinion recognizes the unique attributes of TransCon hGH and how our TransCon technology enables the long-acting release of unmodified somatropin which provides a predictable mode of action without changing the expected safety profile. We are very pleased with our PDCO discussions as the approval of our PIP reflects to our knowledge the first time PDCO has concluded that a clinical development program for a long acting growth hormone treatment is appropriate to support the clinical development in children.

Ascendis submitted a Biologics License Application for TransCon hGH for the treatment of pediatric GHD to the U.S. Food and Drug Administration in June 2020, and the company recently conducted productive meetings with European regulatory personnel, including a pre-submission meeting with EMA and meetings with the rapporteur and co-rapporteur.

About the Paediatric Committee (PDCO)

The Paediatric Committee (PDCO) is the European Medicines Agency's (EMA) scientific committee responsible for activities on medicines for children and to support the development of such medicines in the European Union by providing scientific expertise and defining paediatric needs.

About the Paediatric Investigation Plan (PIP)

A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, to support the authorisation of a medicine for children. All applications for marketing authorisation for new medicines have to include the results of studies as described in an agreed PIP, unless the medicine is exempt because of a deferral or waiver. This requirement also applies when a marketing-authorisation holder wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorised and covered by intellectual property rights.

About TransCon Technology

TransCon refers to transient conjugation. The proprietary TransCon platform is an innovative technology designed to create new therapies that optimize therapeutic effect, including efficacy, safety and dosing frequency. TransCon molecules have three components: an unmodified parent drug, an inert carrier that protects it, and a linker that temporarily binds the two. When bound, the carrier inactivates and shields the parent drug from clearance. When injected into the body, physiologic conditions (e.g., pH and temperature) initiate the release of the active, unmodified parent drug in a predictable manner. Because the parent drug is unmodified, its original mode of action may be maintained. TransCon technology is designed to be applied broadly to a protein, peptide or small molecule in multiple therapeutic areas, and to be used systemically or locally.

About Pediatric Growth Hormone Deficiency (GHD)

Pediatric GHD is a serious orphan disease caused when the pituitary gland does not produce enough growth hormone. Children with GHD are not only characterized by short stature, but they also may experience metabolic abnormalities, psychosocial challenges and poor quality of life.

For decades, the standard of care for GHD has been a daily subcutaneous injection of hGH, which improves growth and overall endocrine health.

About Ascendis Pharma A/S

Ascendis Pharma is applying its innovative platform technology to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.

Ascendis Pharma currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus. The company continues to expand into additional therapeutic areas to address unmet patient needs.

Ascendis is headquartered in Copenhagen, Denmark, with additional offices in Heidelberg and Berlin, Germany, and in Palo Alto and Redwood City, California.

For more information, please visit http://www.ascendispharma.com.

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) our plans to submit a MAA for TransCon hGH to the EMA in the third quarter of 2020, (ii) our ability to apply our platform technology to build a leading, fully integrated biopharma company, (iii) our expectations regarding our ability to create potentially best-in-class therapies and (iv) our product pipeline. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our TransCon hGH, TransCon PTH and TransCon CNP or other development programs; unforeseen expenses related to the development and potential commercialization of TransCon hGH, TransCon PTH and TransCon CNP or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon hGH, TransCon PTH and TransCon CNP or other development programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; our ability to obtain additional funding, if needed, to support our business activities and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, theU.S. Securities and Exchange Commission(SEC), including our Annual Report on Form 20-F filed with the SEC on April 3, 2020. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments we may enter into or make. We do not assume any obligation to update any forward-looking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group. July 2020 Ascendis Pharma A/S.

View post:
Ascendis Pharma A/S Receives Positive Opinion from the Paediatric Committee of the European Medicines Agency on the Agreement of a Paediatric...

Human Growth Hormone hGH Market Latest Research Report 2020:

The Human Growth Hormone hGH report provides an independent information about the Human Growth Hormone hGH industry supported by extensive research on factors such as industry segments size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porters five force analysis, and key companies

Download Premium Sample Copy Of This Report: Download FREE Sample PDF!

In this report, our team offers a thorough investigation of Human Growth Hormone hGH Market, SWOT examination of the most prominent players right now. Alongside an industrial chain, market measurements regarding revenue, sales, value, capacity, regional market examination, section insightful information, and market forecast are offered in the full investigation, and so forth.

Scope of Human Growth Hormone hGH Market:Products in the Human Growth Hormone hGH classification furnish clients with assets to get ready for tests, tests, and evaluations.

Major Company Profiles Covered in This Report

Eli Lilly and Company, Ferring Holding SA, Genentech, Merck & Co., Novo Nordisk, Pfizer, Sandoz International GmbH, Ipsen,

1. To provide a detailed investigation of the market structure alongside conjecture of the different sections and sub-portions of the worldwide Human Growth Hormone hGH Market.

Human Growth Hormone hGH Market Report Covers the Following Segments:

Market segment by Type, the product can be split into

Recombinant Human Growth Hormone (rhGH), Human Growth Hormone (rhGH),

Market segment by Application, split into

Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Others,

Market segment by Regions/Countries, this report covers

United States

Europe

China

Japan

Southeast Asia

India

Central & South America

North America

Europe

Asia-Pacific

South America

Center East and Africa

United States, Canada and Mexico

Germany, France, UK, Russia and Italy

China, Japan, Korea, India and Southeast Asia

Brazil, Argentina, Colombia

Saudi Arabia, UAE, Egypt, Nigeria and South Africa

Table of Content:

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Human Growth Hormone hGH Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Human Growth Hormone hGH Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Human Growth Hormone hGH Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Human Growth Hormone hGH Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Human Growth Hormone hGH Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Human Growth Hormone hGH Market.

Market Forecast:Here, the report offers a complete forecast of the global Human Growth Hormone hGH Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

For detailed informationhttps://brandessenceresearch.biz/Lifesciences-and-Healthcare/Global-and-China-Human-Growth-Hormone-hGH-Market-Research-by-Company-TypeApplication-2013-2025/Summary

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

https://www.marketwatch.com/press-release/solar-street-lighting-system-market-outlook-research-report-information-by-type-disease-size-share-development-growth-and-demand-forecast-2020-2025-2020-05-29?tesla=y

https://www.marketwatch.com/press-release/flexible-food-packaging-market-2020-industry-research-share-trend-global-industry-size-price-future-analysis-regional-outlook-to-2025-covid-19-impact-analysis-2020-05-29?tesla=y

https://www.marketwatch.com/press-release/geographical-information-system-market-is-valued-at-expected-to-reach-usd-1249-billion-by-2025-cagr-1226-2020-05-29?tesla=y

Top Trending Reports:

https://industrywatchnews.com/folding-furniture-market-2020-size-manufacturers-revenue-analysis-growth-opportunities-and-forecast

https://industrywatchnews.com/next-generation-firewall-market-overview-growth-development-factors-application-and-future-prospects

https://teletype.in/@ellinahussey/ZDCm-Ot9v

https://businessstatsnews.com/beard-oil-market-2020-global-demand-key-players-overview-supply-and-consumption

https://marketstatsreport.com/chemotherapy-treatment-market-2020-insights-trends-and-opportunity-analysis-2020-2025

Continued here:
Human Growth Hormone hGH MARKET OVERVIEW WITH DETAILED ANALYSIS, COMPETITIVE LANDSCAPE, FORECAST TO 2025 - 3rd Watch News

It has been a tough enough time for boxing with the whole coronavirus lockdown and then Jarrell Miller comes along to remind us about the curse of drugs within the sport.

iller missed out on a world heavyweight title fight with Anthony Joshua last year after he tested positive for the performance-enhancing drugs GW1516, HGH and IPO. He was to have made his return to the ring this month but has tested positive for GW1516 again, though he is adamant that he did not take the substance on purpose.

Fans and fighters will make their own minds up about whether he is guilty or not of taking it on purpose, but the fact remains that it was found in his system. In my opinion, he should have been chucked out of the sport after last year's positive tests and one thing I will always take pride in when my career is over is that I gave my all doing it the right away, being clean.

This latest controversy as well as the disconcerting rumours I hear about some gyms the States sadly leads me to have a real fear that the use of performance-enhancing drugs is worse than ever in boxing - even though there has been more testing.

Let's be honest, when you see a fighter go from being a light hitter with few knockouts or stoppages to someone who is rocking fighters to their bootstraps, it does raise eyebrows.

Unfortunately, the rumour mill in boxing is growing all the time about who is possibly using PEDs and even four or five years ago that wouldn't have been the case. It seems there is a growing culture that reflects what happened in cycling and athletics - that you have to take them because everyone else is. That's a crying shame and it's not the case, you can't tar every fighter with the same brush but there is a real concern that more and more boxers may be getting away with PED use. That's why it was such a mistake by the World Anti-Doping Association to announce during lockdown that they were not doing any testing. That was just a green light for the cheats to get on the gear!

I have recently filled out my latest form for UKAD to tell them about my whereabouts for the next three months so they can test me whenever they want and it should be the same for every fighter.

I still don't believe the governing bodies are taking the whole issue of drug use seriously enough and you do wonder if it will take a tragedy for those in authority to raise their game.

The problem in America is that they have different rules in each State and that needs to change immediately because the PED curse has to be crushed.

I don't know how anyone can cheat by using the drugs and then gain any sort of satisfaction from winning a fight when they know that they've been juiced to the eyeballs. But it seems that temptation to cheat to earn a living is just too great for some.

Our sport really needs to protect its reputation and be ruthless with PED cheats - they have to be kicked out. Miller is appealing his latest positive test but if that fails then that has to be the end of his ring career.

If, on the other hand, he is given another chance, it sends a signal that it's worth taking the risk of cheating in a sport in which men and women can be maimed for life or killed.

See original here:
Carl Frampton: I fear that drugs use in boxing could be rife and something needs to be done about it - Belfast Telegraph

Intermittent fasting is one of the top lifestyle trends this year not only because we came out of COVID-19 looking a little chubbier and tubbier, but also because it has proven results with (relatively) little effort required. Nevertheless, as with all diets (and diet fads), its important to be properly informed before embarking on a journey of changing your eating habits.

Here, Dr Priya Khorana gives us the ultimate low-down on intermittent fasting, from the perspective of someone who really knows a thing or two about this stuff. Read on, take note, and decide for yourself if youre ready to (stomach) rumble.

Intermittent fasting (IF) is not a diet. It is a timed approach to eating, and unlike a restricted fad diet, it does not specify what foods a person should eat or avoid. To put simply; IF does not change what you eat, it changes when you eat.

It may have some health benefits, including weight loss and improved insulin sensitivity, but it is not suitable for everyone and should be done with careful consideration. People with advanced diabetes or who are on medications for diabetes, people with a history of eating disorders like anorexia and bulimia, and pregnant or breastfeeding women should not attempt intermittent fasting unless under the close supervision of a physician who can monitor them.

Having said that, there are some evidence-based benefits of IF. In men, it has shown to reduce insulin resistance and lower blood sugar levels (and thereby reducing the risk of type 2 diabetes). It has also been shown to reduce oxidative damage and inflammation, thereby slowing down the effects of ageing. Lastly, the insulin levels drop human growth hormone (HGH) increases, which helps facilitate fat burning and muscle gain.

Depending on your IF approach, youre either shortening the eating window each day or engaging in 24-hour fasts one or more times a week. One of the most popular approaches is the 16:8 method, which is when you fast for an eight-hour window this is often the approach I go for. It is vital to stress that folks use an eating approach that works and is sustainable to them.

The 16:8 MethodThis is also called the Leangains Protocol and involves skipping breakfast and restricting your daily eating period to 8 hours, such as 1-9:00 pm. Then you fast for 16 hours in between.

The Eat-Stop-EatThis involves fasting for 24 hours, once or twice a week. For example, you may not eat from dinner one day until dinner the next day.

The 5:2 DietWith this method, you consume only 500-600 calories on two non-consecutive days of the week but eat normally the other 5 days.

As a doctor of nutrition, I will always recommend foods for improved health, including high-fibre, unprocessed, whole foods in all colours and varieties. A mostly plant-based Mediterranean-style diet has been linked to improved health benefits, and in this case, I will suggest this way of life even whilst fasting. Making sure you are nourishing your body as effectively prior to starting your fast will help prevent any feelings of being hangry during the fast.

It is also vital for me to suggest that if you are embarking on an IF journey, staying hydrated is key. Fasting can come with some initial side effects, such as increased hunger, low blood sugar, headache, irritability, dizziness, and fatigue so please embark with caution.

Limiting your dining window does not give you an excuse to binge eat especially on unhealthy foods because you will not see the benefits. Eating unwholesome (read: junk) food in a shortened feeding window on the IF diet may also put you at risk of deficiencies in key nutrients such as calcium, iron, protein, and fibre, all of which are essential for normal biological function.

What you need to do is consume a diet rich in fruits and vegetables, whole-grains, and sufficient lean protein and healthy fat boosting important antioxidants and nutrients which all result in an increased lifespan and reduces the risks of developing lifestyle-related chronic diseases.

What is important to emphasise is that the goal of IF is to maintain a healthy amount of calories for your body during the fast so you do not rebound eat.

For those starting out, I suggest implementing a 12-hour fasting/12-hour eating window and building up from there, eventually finding a schedule that works best for you. The most important thing is breaking your fast with fresh, unprocessed, nutrient-dense whole foods, prioritising healthy sources of protein and good fats, all while limiting junk foods that negate any benefits of IF.

For more super-nutritious advice and information, be sure to follow the fabulous Priya over onInstagramandFacebook.

Featured and hero image: Courtesy Malvestida Magazine/Unsplash

This story first appeared on Lifestyle Asia Bangkok.

Originally posted here:
What is intermittent fasting and what to actually eat while intermittent fasting - Lifestyle Asia

COVID-19 (Coronavirus) has resulted in many advantages and disadvantages for companies in the Human Growth Hormone (HGH) market. Research report of this Human Growth Hormone (HGH) market is highlights key strategies that can help reduce the impact of COVID-19 on diverse business practices.

Analysts of Fact.MR, in a recently published market study, shares important factors that are expected to shape the growth of the Human Growth Hormone (HGH) market over the forecast period (20XX-20XX). The current trends, market drivers, strategic collaborations, and threats are thoroughly evaluated to provide a clear understanding of the current market landscape and the course the Human Growth Hormone (HGH) market is likely to take over the upcoming decade.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1389

According to the report, the Human Growth Hormone (HGH) market is poised to register a CAGR growth of ~XX% throughout the forecast period owing to several key factors including growing investments in the Human Growth Hormone (HGH) space, innovations with a rise in the number of research and development projects. Fact.MR excels in latest research techniques while curating the market study and gather data from credible and trusted primary and secondary sources.

Important doubts pertaining to the Human Growth Hormone (HGH) market addressed in the report:

The Human Growth Hormone (HGH) market study provides a detailed understanding of the major players operating in the Human Growth Hormone (HGH) market. Some of the leading players discussed

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1389

Human Growth Hormone (HGH) market segments covered in the report:

Competitive landscape

Comprehensive SWOT analysis of established market players is provided in the report along with critical data including the sales strategy, marketing strategy and pricing strategy adopted by each market player.

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1389

Key takeaways that add value to our clients business needs?

Original post:
Global trade impact of the Coronavirus Human Growth Hormone (HGH) Market Poised for Steady Growth in the Future 2018 to 2028 - Owned

Page 19«..10..18192021..3040..»

Home » Hgh » Page 19